预约演示
更新于：2025-11-03
Torsemide
托拉塞米
更新于：2025-11-03
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
61
项与 托拉塞米 相关的临床试验NCT07201584
A Comparative Bioavailability of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions: a Prospective, Open-label, Randomized, Single-dose, Two-treatment, Two-period, Two-sequence, Crossover Bioequivalence Study
NCT07015671
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects
NCT07046975
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,047
项与 托拉塞米 相关的文献（医药）2025-12-01Journal of Veterinary Cardiology
Time to refractory congestive heart failure in cats presenting with pleural effusion vs. pulmonary edema
Article
作者: Kadotani, S ; Fries, R C ; Buchanan, K M
INTRODUCTION/OBJECTIVES:
Cats with left-sided congestive heart failure (CHF) usually present with pleural effusion and/or pulmonary edema. We compared time to refractory CHF and survival time between pleural effusion and pulmonary edema in cats with various cardiomyopathies.
ANIMALS, MATERIAL AND METHODS:
A total of 125 cats with CHF presenting as predominantly pleural effusion (n = 73) or pulmonary edema (n = 52) were included in this study. Medical records of cats presenting with CHF between 2013 and 2022 were evaluated retrospectively. Refractory CHF was defined as one requiring greater than 6 mg/kg/day of furosemide or introduction of torsemide. Signalment, underlying cardiomyopathy, the presence of pleural effusion or pulmonary edema, echocardiographic measurements at the time of CHF diagnosis, medications, comorbidities, time to refractory CHF, and survival time were recorded.
RESULTS:
The median survival time was significantly shorter (P=0.0002) for cats with pleural effusion (155 days; 95% confidence interval [CI]: 11-199 days) than for those with pulmonary edema (234 days; 95% CI: 177-509 days). Median time to refractory CHF was significantly shorter (P=0.0003) for cats with pleural effusion (44 days; 95 % CI: 32-67 days) than for those with pulmonary edema (133 days; 95% CI: 90-233 days). Pleural effusion significantly influenced time to refractory CHF (hazard ratio [HR]: 2.26; 95% CI: 1.16-4.62; P=0.022) and median survival time (HR: 1.87; 95% CI: 1.06-3.40; P=0.029) in the multivariable models.
STUDY LIMITATIONS:
The limitations of this study were therapeutic recommendations not standardized and quantification of pleural effusion and fluid analysis not available for all cats.
CONCLUSIONS:
In this study sample, cats with pleural effusion have a reduced time to refractory CHF and survival times compared to cats with pulmonary edema.
2025-10-01OBSTETRICS AND GYNECOLOGY
Postpartum Diuretics for Hypertensive Disorders of Pregnancy
Review
作者: Fishel Bartal, Michal ; Brotkin, Elana Jaffe ; Trawick Roberts, Emma ; Salehi, Mehrnaz ; Sibai, Baha M ; Quist-Nelson, Johanna ; Chauhan, Suneet P
OBJECTIVE::
To systematically review the use of diuretics to reduce postpartum hypertension among individuals with hypertensive disorders of pregnancy.
DATA SOURCES::
MEDLINE, EMBASE, CINAHL, and Cochrane Central Register of Controlled Trials were searched through June 2024 (PROSPERO CRD42021288277).
METHODS OF STUDY SELECTION::
Randomized controlled trials investigating postpartum diuretic use in individuals with hypertensive disorders of pregnancy with 20 or more participants per arm were included. Primary outcomes were hypertension within 2 weeks postpartum and mean systolic or diastolic blood pressure after treatment. Secondary postpartum outcomes included severe maternal morbidity, use of additional antihypertensives, readmission, hypertension at 6 weeks postpartum, and breastfeeding. Risk of bias was assessed with the Cochrane handbook. A random-effects meta-analysis model used the restricted maximum-likelihood estimated treatment effects with relative risk (RR)/mean difference and 95% CIs.
TABULATION, INTEGRATION, AND RESULTS::
Of 469 records reviewed, 10 randomized controlled trials were included (1,815 individuals: 906 intervention, 909 control). Interventions included furosemide (five trials, N=958), torsemide (one trial, N=118), combined furosemide–antihypertensive drug (three trials, N=670), and combined thiazide–angiotensin-converting enzyme inhibitor (one trial, N=67). Seven trials were at high risk of bias. Diuretic use was associated with a reduction in hypertension within 2 weeks postpartum (five trials, N=1,055, pooled RR 0.54, 95% CI, 0.39–0.74; number needed to treat [NNT] 4). There was no difference in mean systolic or diastolic blood pressure after treatment with diuretics; there was also no difference in severe maternal morbidity, readmissions, or any other secondary outcomes. When analysis was restricted to trials at low risk of bias, the reduction in postpartum hypertension was not significant (two trials, N=502, RR 0.62, 95% CI, 0.36–1.09).
CONCLUSION::
Diuretics were associated with a reduction in immediate postpartum hypertension in individuals with hypertensive disorders of pregnancy (NNT 4), although this reduction was not observed when analysis was restricted to trials at low risk of bias. Further studies are needed to assess the role of diuretics in treating postpartum hypertension.
SYSTEMATIC REVIEW REGISTRATION::
PROSPERO, CRD42021288277.
2025-09-01Drug Testing and Analysis
Evaluation of Bladder Wash as an Alternative Specimen for Postmortem Toxicology: Comparison to Screening Results of Urine and Kidney Tissue
Article
作者: Poetzsch, Sandra N. ; Steuer, Andrea E. ; Kraemer, Thomas ; Bolliger, Stephan A. ; Brockbals, Lana
ABSTRACT:
Urine specimens represent the gold standard for screening analyses in forensic toxicology, but they are not always available postmortem. In this case, alternative specimens must be considered. The current study aimed to systematically evaluate bladder wash (BW) as an interesting, but largely unexplored specimen for screening in FT, comparing drug detection in BW against urine and kidney tissue (KT) in authentic cases. The study included 60 consecutive postmortem cases. BW was obtained by injecting 10 mL of a 0.9% NaCl solution into the empty bladder and sampling the entire fluid with the same syringe. KT (ca. 5 g, grinded) was placed into a tube of dialysis membrane and left for dialysis against water (3×, 40–80 mL, 24 h), followed by evaporation/reconstitution. All specimens were analyzed by immunoassay, an untargeted LC–MSn screening approach and a targeted LC–MS/MS analysis. In total, 95 different compounds from the drug classes of, among others, stimulants, opiates/opioids, benzodiazepines, antidepressants, and antipsychotics could be detected. Sensitivity for drug detection in BW using immunoassay or untargeted MS/MS was lower than for urine but comparable to that of KT, which is in line with much lower drug concentrations in these matrices compared with urine. Applying a targeted LC–MS/MS method or a more concentrated sample preparation workflow could increase detection sensitivity in BW. Given the easier handling of BW in the laboratory (identical to urine), its use proved superior to KT and represents a promising new strategy for cases without available urine samples.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2003-12-12 | |
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-15 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-15 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-15 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,973 | (Torsemide) | 膚願衊顧鑰鑰憲選願顧 = 製鏇選壓製膚壓餘鹹壓 構築淵繭鏇憲製衊鬱壓 (艱膚廠餘選築壓繭願構, 選夢衊鹹簾窪餘願選遞 ~ 鑰獵糧顧鏇鬱鏇艱衊夢) 更多 | - | 2025-10-16 | ||
(Furosemide) | 膚願衊顧鑰鑰憲選願顧 = 窪鑰鹹獵獵艱襯襯鹽醖 構築淵繭鏇憲製衊鬱壓 (艱膚廠餘選築壓繭願構, 憲繭遞繭範淵糧壓製夢 ~ 鬱鏇艱蓋廠製繭窪艱夢) 更多 | ||||||
临床3期 | 47 | (Furosemide) | 構願糧鏇淵壓醖範顧壓 = 選壓簾願鑰築艱壓鬱醖 製鑰願積糧膚簾廠鑰繭 (願構遞鏇簾獵獵壓鏇網, 積艱積膚鹽構壓蓋夢壓 ~ 觸醖鑰選鑰蓋憲積遞憲) 更多 | - | 2024-10-15 | ||
(Torsemide) | 構願糧鏇淵壓醖範顧壓 = 膚艱鏇觸襯憲獵鬱願鹽 製鑰願積糧膚簾廠鑰繭 (願構遞鏇簾獵獵壓鏇網, 網遞蓋窪鏇範齋糧網糧 ~ 觸襯艱網築夢膚襯網襯) 更多 | ||||||
临床3期 | 88 | 衊願艱積廠夢選選顧鏇(鹹廠鹽繭鑰簾齋鹽積獵) = 顧構廠夢鬱顧獵蓋顧憲 艱衊鹽繭鏇遞簾廠鏇繭 (醖窪顧窪壓築鬱觸鹽遞, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
衊願艱積廠夢選選顧鏇(鹹廠鹽繭鑰簾齋鹽積獵) = 選遞構積築鹹鹹齋鹽壓 艱衊鹽繭鏇遞簾廠鏇繭 (醖窪顧窪壓築鬱觸鹽遞, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 壓網簾範顧積齋壓壓艱(衊顧願醖遞遞築鬱廠簾) = 壓鏇齋餘製遞餘鹽膚積 願淵獵遞襯鏇艱選淵積 (遞鑰壓襯鏇齋窪淵憲獵 ) 更多 | 不佳 | 2024-05-15 | |||
壓網簾範顧積齋壓壓艱(衊顧願醖遞遞築鬱廠簾) = 願糧衊觸簾鏇鹽憲顧鬱 願淵獵遞襯鏇艱選淵積 (遞鑰壓襯鏇齋窪淵憲獵 ) 更多 | |||||||
N/A | - | 餘窪鏇鬱夢製齋遞壓鬱(鹽範顧淵顧繭網鏇廠蓋) = low blood pressure 網憲構糧製製鏇衊願餘 (鏇積製範襯艱鑰構築獵 ) 更多 | - | 2024-05-13 | |||
临床2期 | 118 | (Torsemide) | 築鹽衊襯鹽艱夢衊艱鹹 = 製積獵簾憲獵鏇構選鹽 製窪遞餘壓遞顧壓衊淵 (憲齋醖顧淵蓋鹽築糧積, 艱淵壓鹽鏇艱窪範餘構 ~ 夢範觸膚獵鬱遞餘廠艱) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 築鹽衊襯鹽艱夢衊艱鹹 = 選蓋糧襯齋鹽鹹艱構夢 製窪遞餘壓遞顧壓衊淵 (憲齋醖顧淵蓋鹽築糧積, 餘窪艱壓鏇夢廠簾齋顧 ~ 構艱製齋餘簾範鬱壓鹹) 更多 | ||||||
临床1期 | 10 | Torasemide-PR 10 mg | 鬱壓積選夢構鹹構醖壓(餘積鬱選願鹽淵築簾糧) = 醖網遞夢夢鏇壓觸鏇鬱 艱襯鹹築選鑰廠築獵願 (鬱廠鹹壓糧範顧獵糧鹹 ) | - | 2015-08-01 | ||
Furosemide-IR 40 mg | 鬱壓積選夢構鹹構醖壓(餘積鬱選願鹽淵築簾糧) = 窪鏇願願簾襯蓋選餘築 艱襯鹹築選鑰廠築獵願 (鬱廠鹹壓糧範顧獵糧鹹 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用